Zymeworks Inc., a Vancouver (BC), Canada-based biotechnology company focused on the development of innovative antibody-based therapeutics, closed a $3.2m financing.
The round consists of a follow-on institutional investment by CTI Life Sciences Fund, L.P. which led the company’s previous financing in 2009.
Zymeworks will use the funds to advance its antibody-engineering platform, ZymeCAD™, and research programs focused on the development of its protein therapeutics pipeline.
In connection with the financing, Dr. Donald Drakeman, a Venture Partner at Advent Venture Partners LLP, will be joining the company’s board of directors as an independent board member.
FinSMEs
29/06/2010